Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show ...

In the experiments, the dual-adjuvant vaccine was found to produce a wider diversity of antibodies to protect against an HIV protein than with either single adjuvant or none at all.

WASHINGTON — The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that could protect millions – although it’s unclear how many in ...

In two studies, scientists at Gilead, which developed lenacapavir, showed that the drug was 100% effective at protecting cisgender women from becoming HIV positive as compared to daily oral pills ...

The world’s only twice-a-year shot to prevent HIV could stop transmission — if people can get it It’s the first step in an anticipated global rollout that could protect millions.

WASHINGTON D.C., DC — The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that could protect millions – although it's ...

WASHINGTON D.C., DC — The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that could protect millions – although it's ...

Condoms help guard against HIV infection if used properly but what's called PrEP — regularly using preventive medicines such as the daily pills or a different shot given every two months — is ...

WASHINGTON D.C., DC — The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that could protect millions – although it's ...

WASHINGTON D.C., DC — The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that could protect millions – although it's ...

WASHINGTON D.C., DC — The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that could protect millions – although it's ...

Wednesday's approval marks the first step in an anticipated global rollout that experts say could protect millions.